Cancer Gene Therapy Market Research Report
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Indication Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Gene Therapy Market
5.1. COVID-19 Landscape: Cancer Gene Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Gene Therapy Market, By Indication
8.1. Cancer Gene Therapy Market, by Indication
8.1.1 Large B-Cell Lymphoma
8.1.1.1. Market Revenue and Forecast
8.1.2. Multiple Myeloma
8.1.2.1. Market Revenue and Forecast
8.1.3. Acute Lymphoblastic Leukemia (ALL)
8.1.3.1. Market Revenue and Forecast
8.1.4. Melanoma (lesions)
8.1.4.1. Market Revenue and Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Forecast
Chapter 9. Global Cancer Gene Therapy Market, By Route of Administration
9.1. Cancer Gene Therapy Market, by Route of Administration
9.1.1. Intravenous
9.1.1.1. Market Revenue and Forecast
9.1.2. Others
9.1.2.1. Market Revenue and Forecast
Chapter 10. Global Cancer Gene Therapy Market, By Vector Type
10.1. Cancer Gene Therapy Market, by Vector Type
10.1.1. Lentivirus
10.1.1.1. Market Revenue and Forecast
10.1.2. RetroVirus & gamma RetroVirus
10.1.2.1. Market Revenue and Forecast
10.1.3. AAV
10.1.3.1. Market Revenue and Forecast
10.1.4. Modified Herpes Simplex Virus
10.1.4.1. Market Revenue and Forecast
10.1.5. Adenovirus
10.1.5.1. Market Revenue and Forecast
10.1.6. Others
10.1.6.1. Market Revenue and Forecast
Chapter 11. Global Cancer Gene Therapy Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Indication
11.1.2. Market Revenue and Forecast, by Route of Administration
11.1.3. Market Revenue and Forecast, by Vector Type
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Indication
11.1.4.2. Market Revenue and Forecast, by Route of Administration
11.1.4.3. Market Revenue and Forecast, by Vector Type
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Indication
11.1.5.2. Market Revenue and Forecast, by Route of Administration
11.1.5.3. Market Revenue and Forecast, by Vector Type
11.2. Europe
11.2.1. Market Revenue and Forecast, by Indication
11.2.2. Market Revenue and Forecast, by Route of Administration
11.2.3. Market Revenue and Forecast, by Vector Type
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Indication
11.2.4.2. Market Revenue and Forecast, by Route of Administration
11.2.4.3. Market Revenue and Forecast, by Vector Type
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Indication
11.2.5.2. Market Revenue and Forecast, by Route of Administration
11.2.5.3. Market Revenue and Forecast, by Vector Type
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Indication
11.2.6.2. Market Revenue and Forecast, by Route of Administration
11.2.6.3. Market Revenue and Forecast, by Vector Type
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Indication
11.2.7.2. Market Revenue and Forecast, by Route of Administration
11.2.7.3. Market Revenue and Forecast, by Vector Type
11.3. APAC
11.3.1. Market Revenue and Forecast, by Indication
11.3.2. Market Revenue and Forecast, by Route of Administration
11.3.3. Market Revenue and Forecast, by Vector Type
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Indication
11.3.4.2. Market Revenue and Forecast, by Route of Administration
11.3.4.3. Market Revenue and Forecast, by Vector Type
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Indication
11.3.5.2. Market Revenue and Forecast, by Route of Administration
11.3.5.3. Market Revenue and Forecast, by Vector Type
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Indication
11.3.6.2. Market Revenue and Forecast, by Route of Administration
11.3.6.3. Market Revenue and Forecast, by Vector Type
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Indication
11.3.7.2. Market Revenue and Forecast, by Route of Administration
11.3.7.3. Market Revenue and Forecast, by Vector Type
11.4. MEA
11.4.1. Market Revenue and Forecast, by Indication
11.4.2. Market Revenue and Forecast, by Route of Administration
11.4.3. Market Revenue and Forecast, by Vector Type
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Indication
11.4.4.2. Market Revenue and Forecast, by Route of Administration
11.4.4.3. Market Revenue and Forecast, by Vector Type
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Indication
11.4.5.2. Market Revenue and Forecast, by Route of Administration
11.4.5.3. Market Revenue and Forecast, by Vector Type
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Indication
11.4.6.2. Market Revenue and Forecast, by Route of Administration
11.4.6.3. Market Revenue and Forecast, by Vector Type
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Indication
11.4.7.2. Market Revenue and Forecast, by Route of Administration
11.4.7.3. Market Revenue and Forecast, by Vector Type
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Indication
11.5.2. Market Revenue and Forecast, by Route of Administration
11.5.3. Market Revenue and Forecast, by Vector Type
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Indication
11.5.4.2. Market Revenue and Forecast, by Route of Administration
11.5.4.3. Market Revenue and Forecast, by Vector Type
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Indication
11.5.5.2. Market Revenue and Forecast, by Route of Administration
11.5.5.3. Market Revenue and Forecast, by Vector Type
Chapter 12. Company Profiles
12.1. Novartis AG.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol Myers Squibb (Juno Therapeutics).
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bluebird Bio, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Adaptimmune Therapeutics plc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Intellia Therapeutics, Inc..
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Intellia Therapeutics, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. CRISPR Therapeutics AG.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Poseida Therapeutics, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sorrento Therapeutics, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. GenSight Biologics
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers